The second trial provides men with metastatic prostate cancer access to prostate-specific membrane antigen (PSMA)-targeted therapy prior to chemotherapy. Currently, PSMA-targeted therapy is only available after chemotherapy. However, phase III clinical trials have shown that PSMA-targeted therapies are more effective and have lower toxicities than chemotherapies for prostate cancer.
"The 177Lu-PNT2002 Expanded Access Protocol provides PSMA-targeted therapy earlier in the course of disease," said Dr. Ulaner. "We aim to enhance treatment options for patients with metastatic prostate cancer, while avoiding the side effects of chemotherapy.
NCT04662580 - All about ARX517 as Monotherapy
primary tumor
Help Understanding My Dad's Biopsy Scores
A technical question on Radiation
Introduction and asking for help interpreting latest scan results and thoughts on future treatment plan please.
